Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer

Urology

Volumn 58, Issue 2 SUPPL. 1, 2001, Pages 123-126

  Peehl, Donna M ^a,b   Seto, Eugene ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYTOCHROME P450; KETOCONAZOLE; LIAROZOLE; OXYGENASE; PROSTATE SPECIFIC ANTIGEN;

CONFERENCE PAPER; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL CULTURE; VITAMIN D DEFICIENCY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; DRUG SYNERGISM; HUMANS; KETOCONAZOLE; MALE; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 0034908713     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01254-7     Document Type: Conference Paper

References (24)

1. Ketoconazole; a novel and rapid treatment for advanced prostatic cancer
2. Ketoconazole blocks testosterone synthesis
3. Ketoconazole blocks adrenal steroid synthesis
4. Ketoconazole; a possible direct cytotoxic effect on prostate carcinoma cells
5. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes
6. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines
7. Vitamin D and prostate cancer
8. Vitamin D and prostate cancer risk
9. Vitamin D and prostate cancer
10. Toward therapeutic intervention of cancer by vitamin D compounds
11. Phase II trial of oral 1,25- dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
12. Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells
13. 3 in seven human prostatic carcinoma cell lines
14. 3 receptors and actions in human prostate cancer cell lines
15. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity
16. Clinical pharmacokinetics of ketoconazole
17. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis)
18. Hypovitaminosis D in medical inpatients
19. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength
20. Osteoporosis after orchiectomy for prostate cancer
21. Effects of orchidectomy and different modes of high dose estrogen treatment on circulating 'free' and total 1,25-dihydroxyvitamin D in patients with prostatic cancer
22. 3) for the treatment of psoriasis